MindMed readying Phase III trials for LSD therapy to treat anxiety

By / / Finance / 1 minute of reading




MindMed Inc. said Tuesday it’s on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting.



Source link

About The Author

Avatar of Amanda Pierce
Amanda Pierce is a writer who has covered sports, education, and tech for Highland Loch Press. She also writes about her hobbies—which include hiking, traveling to new places, and cooking.

Start typing and press enter to search

Scroll to Top